This inventor holds 1 USPTO granted patent, plus 1 CIPO patent. Top assignee: Daiichi Sankyo Company, Limited. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Kazutaka Yoshihara: Innovator in Cancer Therapy
Introduction
Kazutaka Yoshihara is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of cancer therapy, particularly in addressing drug-resistant cancer. His innovative approach has garnered attention in the medical community.
Latest Patents
Kazutaka Yoshihara holds a patent for a groundbreaking therapy aimed at drug-resistant cancer. The patent, titled "Therapy for Drug-Resistant Cancer by Administration of Anti-HER2 Antibody/Drug Conjugate," showcases his commitment to advancing cancer treatment options. He has 1 patent to his name, reflecting his dedication to innovation in this critical area.
Career Highlights
Yoshihara is currently employed at Daiichi Sankyo Company, Limited, where he continues to work on developing effective cancer therapies. His role at this esteemed company allows him to collaborate with other experts in the field and contribute to significant advancements in medical science.
Collaborations
Kazutaka Yoshihara has worked alongside talented colleagues, including Takahiro Jikoh and Yusuke Ogitani. Their collaborative efforts have been instrumental in driving forward the research and development of innovative cancer therapies.
Conclusion
Kazutaka Yoshihara's work in cancer therapy exemplifies the impact of innovation in medicine. His patent and ongoing contributions at Daiichi Sankyo Company, Limited highlight his commitment to improving treatment options for patients facing drug-resistant cancer.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile